Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation (HALT)

June 16, 2026 updated by: Rennes University Hospital
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
400

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
      • Chambray-lès-Tours, France, 37170
        • Recruiting
        • 08_CHRU de Tours Hôpital Trousseau
        • Principal Investigator:
          • Ephrem SALAME, MD
        • Contact:
      • Clichy, France, 92110
        • Recruiting
        • 03_APHP Hôpital Beaujon
        • Contact:
        • Principal Investigator:
          • Claire FRANCOZ, MD
        • Sub-Investigator:
          • Emmanuel WEISS, MD
      • Lille, France, 59000
        • Recruiting
        • 04_CHU de Lille Hôpital Huriez
        • Principal Investigator:
          • Sébastien DHARANCY, MD
        • Contact:
        • Sub-Investigator:
          • Gilles LEBUFFE, MD
      • Lyon, France, 69004
        • Recruiting
        • 05_HCL Hôpital de la Croix Rousse
        • Sub-Investigator:
          • CELINE GUICHON, MD
        • Principal Investigator:
          • Marie-Charlotte DELIGNETTE, MD
        • Contact:
      • Montpellier, France, 34295
        • Recruiting
        • 06_CHU de Montpellier Hôpital St Eloi
        • Principal Investigator:
          • Georges Philippe PAGEAUX, MD
        • Sub-Investigator:
          • Clément MONET, MD
        • Contact:
      • Pessac, France, 33604
        • Recruiting
        • 02_CHU de Bordeaux - Hôpital Haut Leveque
        • Contact:
        • Principal Investigator:
          • Antoine DEWITTE, MD
        • Sub-Investigator:
          • Jean Baptiste HIRIART, MD
      • Rennes, France, 35000
        • Recruiting
        • 01_CHU de Rennes Hôpital Pontchaillou
        • Contact:
        • Principal Investigator:
          • Jean-Marc TADIE, MD
        • Sub-Investigator:
          • Pauline HOUSSEL-DEBRY, MD
      • Villejuif, France, 94804
        • Recruiting
        • 09_APHP Hôpital Paul Brousse
        • Contact:
        • Principal Investigator:
          • Philippe Ichaï, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male and female subjects equal or above 18 yrs old.
  • Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
  • Capability of understanding the purpose and risks of the study.
  • Written informed consent

Exclusion Criteria:

  • Fulminant hepatitis
  • Kidney injury at baseline (Estimated Glomerular Filtration Rate < 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
  • Use of an induction agent Basiliximab at liver transplantation
  • Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: 30 g/L or below
Receive Human Albumin 20% Solution when albumin serum concentration is at 30 g/L or below
Drug: Albumin administration
when albumin serum concentration is at 30 g/L or below
Active Comparator: 20 g/L or below
receive Human Albumin 20% Solution when albumin serum concentration is at 20 g/L or below
Drug: Albumin administration
when albumin serum concentration is at 30 g/L or below

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Acute Kindey Injury at Day 7
Time Frame: 7 days after liver transplantation
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (=30 g/L) for five days diminishes rate of Acute Kindey Injury at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).
7 days after liver transplantation

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Occurrence and Severity of each Acute Kindey Injury during the first 7 days after liver transplantation
Time Frame: 7 days after liver transplantation
Occurrence and Severity of each Acute Kindey Injury during the first 7 days after liver transplantation
7 days after liver transplantation
hospital length of stay
Time Frame: 28 days
hospital length of stay
28 days
occurrence of calcineurin inhibitor induced neurotoxicity
Time Frame: 28 days
occurrence of calcineurin inhibitor induced neurotoxicity
28 days
occurence of calcineurin inhibitor withdraw
Time Frame: 28 days
occurence of calcineurin inhibitor withdraw
28 days
occurrence of postoperative infections
Time Frame: 28 days
occurrence of postoperative infections
28 days
occurrence of acute graft rejection
Time Frame: 28 days
occurrence of acute graft rejection
28 days
occurrence of early graft dysfunction
Time Frame: 28 days
occurrence of early graft dysfunction
28 days
duration of mechanical ventilation
Time Frame: 28 days
duration of mechanical ventilation
28 days
reintubation rate
Time Frame: 28 days
reintubation rate
28 days
Intensive Care Unit length of stay
Time Frame: 28 days
Intensive Care Unit length of stay
28 days
Intensive Care Unit readmission rate
Time Frame: 28 days
Intensive Care Unit readmission rate
28 days
All cause mortality
Time Frame: 28 days
All cause mortality
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Rennes University Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Ministry of Health, France

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Pauline HOUSSEL-DEBRY, MD, Rennes University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 26, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 26, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 26, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 30, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 30, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 2, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 35RC22_9739_HALT
  • 2024-514804-14-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings